What is the most recent FDA action against Lupin Pharmaceuticals Inc.?

The most recent FDA event Argus HQ has on file for Lupin Pharmaceuticals Inc. is dated 2026-07-08, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Does Argus HQ track new FDA actions for Lupin Pharmaceuticals Inc. automatically?

Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Lupin Pharmaceuticals Inc. is observed, this page's event count and history update automatically.

How many FDA actions does Argus HQ track for Lupin Pharmaceuticals Inc.?

4 total: 0 warning letters, 4 recalls, 0 approval records, and 0 Form 483 inspection citations.

What is the most recent FDA action on file for Lupin Pharmaceuticals Inc.?

July 8, 2026. Argus HQ ingests new FDA enforcement records daily.

Lupin Pharmaceuticals Inc. — FDA Enforcement History

FDA action counts

Total FDA actions	4
Warning letters	0
Recalls	4
Approval records	0
Form 483 inspection citations	0
Most recent action	July 8, 2026

In short: Argus HQ has recorded 3 FDA events for Lupin Pharmaceuticals Inc.: 0 warning letters, 3 recalls, 0 approvals, and 0 inspection 483 observations. These events span from 2026-05-27 to 2026-07-08. The most severe rating Argus HQ has assigned across this history is "high". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Enforcement history

On 2026-07-08, Argus HQ recorded an FDA recall for Lupin Pharmaceuticals Inc., rated "high" severity in Argus HQ's classification: Lupin Pharmaceuticals Inc. — Class II recall: prednisoLONE Acetate Ophthalmic Suspension, USP, 1%, Rx only, Sterile, a) 5 mL (…. On 2026-07-08, Argus HQ recorded an FDA recall for Lupin Pharmaceuticals Inc., rated "medium" severity in Argus HQ's classification: Lupin Pharmaceuticals Inc. — Class ? recall: Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection USP, 1mg per…. On 2026-05-27, Argus HQ recorded an FDA recall for Lupin Pharmaceuticals Inc., rated "high" severity in Argus HQ's classification: Lupin Pharmaceuticals Inc. — Class II recall: Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Ph…. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. Lupin Pharmaceuticals Inc. has 3 separate FDA recalls on file, more than a single isolated recall event. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Frequently asked questions

What is the most recent FDA action against Lupin Pharmaceuticals Inc.?: The most recent FDA event Argus HQ has on file for Lupin Pharmaceuticals Inc. is dated 2026-07-08, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
Does Argus HQ track new FDA actions for Lupin Pharmaceuticals Inc. automatically?: Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Lupin Pharmaceuticals Inc. is observed, this page's event count and history update automatically.
How many FDA actions does Argus HQ track for Lupin Pharmaceuticals Inc.?: 4 total: 0 warning letters, 4 recalls, 0 approval records, and 0 Form 483 inspection citations.
What is the most recent FDA action on file for Lupin Pharmaceuticals Inc.?: July 8, 2026. Argus HQ ingests new FDA enforcement records daily.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Verified from FDA.gov · Last updated: Jul 8, 2026

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). Lupin Pharmaceuticals Inc. — FDA Enforcement History. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/company/lupin-pharmaceuticals-inc

MLA

"Lupin Pharmaceuticals Inc. — FDA Enforcement History." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/company/lupin-pharmaceuticals-inc.

Chicago

Argus HQ Research. "Lupin Pharmaceuticals Inc. — FDA Enforcement History." Digital Empire Holdings LLC. Accessed August 27, 2026. https://argushq.ai/company/lupin-pharmaceuticals-inc.

BibTeX

@misc{argushq_argushq_ai_company_lupin_pharmaceuticals_inc_2026,
  title = {Lupin Pharmaceuticals Inc. — FDA Enforcement History},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/company/lupin-pharmaceuticals-inc},
  note = {Accessed: August 27, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗